e12507 Background: The addition of pembrolizumab (PEM) to neoadjuvant chemotherapy (NAC) has been shown to significantly improve pathological complete response (pCR) rates in patients with early-stage triple-negative breast cancer (TNBC). However, long-term prognostic outcomes in real-world clinical practice, specifically for patients who achieve pCR, have not been sufficiently verified. This study evaluated the efficacy and safety of PEM-combined regimens, with a specific focus on the prognosti